GC Biopharma said on the 24th that its U.S. subsidiary ABO Plasma has introduced a new plasma collection technology. By reflecting donors' body mass index (BMI—the value obtained by dividing weight by height squared) and hematocrit, collections can be tailored to an individual's physical condition.
The company said it can increase efficiency while maintaining donor safety. It reduces the burden caused by excessive collection and, when needed, appropriately increases the collection volume. ABO Plasma has introduced the technology at all of its operating plasma centers.
Chief Executive Heo Eun-cheol of GC Biopharma said, "We will strengthen our global plasma business competitiveness."
※ This article has been translated by AI. Share your feedback here.